Edition:
United States

Circassia Pharmaceuticals PLC (CIRCI.L)

CIRCI.L on London Stock Exchange

18.65GBp
23 Aug 2019
Change (% chg)

0.05 (+0.27%)
Prev Close
18.60
Open
18.60
Day's High
18.65
Day's Low
18.50
Volume
243,566
Avg. Vol
3,360,926
52-wk High
82.70
52-wk Low
13.25

Latest Key Developments (Source: Significant Developments)

Circassia Pharmaceuticals Appoints Jonathan Emms To Newly-Created COO Role
Monday, 12 Aug 2019 02:00am EDT 

Aug 12 (Reuters) - Circassia Pharmaceuticals PLC ::CIRCASSIA PHARMACEUTICALS PLC - ANNOUNCES APPOINTMENT OF JONATHAN EMMS TO NEWLY-CREATED ROLE OF CHIEF OPERATING OFFICER.CIRCASSIA PHARMACEUTICALS PLC - SENIOR VICE PRESIDENT OF RESEARCH AND DEVELOPMENT ROD HAFNER WILL STEP DOWN FROM BOARD.  Full Article

Woodford Investment Management Cuts Stake To 19.95% From 24.47% In Circassia Pharmaceuticals
Monday, 8 Jul 2019 12:02pm EDT 

July 8 (Reuters) - Circassia Pharmaceuticals PLC ::WOODFORD INVESTMENT MANAGEMENT LTD CUTS STAKE TO 19.95% FROM 24.47% IN CIRCASSIA PHARMACEUTICALS PLC - FILING.  Full Article

Circassia Pharma Says Commercial Rights Acquired From AIT Therapeutics
Thursday, 24 Jan 2019 02:00am EST 

Jan 24 (Reuters) - Circassia Pharmaceuticals PLC ::CIRCASSIA PHARMA PLC - COMMERCIAL RIGHTS ACQUIRED FROM AIT THERAPEUTICS.CIRCASSIA PHARMACEUTICALS PLC - ENTERED INTO A DEFINITIVE AGREEMENT TO ACQUIRE EXCLUSIVE COMMERCIALISATION RIGHTS FROM AIT THERAPEUTICS INC.CIRCASSIA PHARMACEUTICALS - COMMERCIALISATION RIGHTS TO ITS VENTILATOR COMPATIBLE NITRIC OXIDE PRODUCT, AIRNOVENT, IN UNITED STATES AND CHINA.CIRCASSIA PHARMACEUTICALS PLC - ANTICIPATES APPLYING TO US FDA FOR PREMARKET APPROVAL (PMA) FOR AIRNOVENT IN Q2 2019 FOR USE IN TREATMENT OF PPHN.CIRCASSIA PHARMACEUTICALS PLC - AIT PLANS TO SEEK A LABEL EXTENSION FOR PRODUCT'S USE IN A RELATED INDICATION.CIRCASSIA PHARMACEUTICALS PLC - CIRCASSIA WILL PAY AIT INITIAL CONSIDERATION OF $7.35 MILLION.CIRCASSIA PHARMACEUTICALS PLC - COMPANY WILL PAY TIERED ROYALTY PAYMENTS BASED ON GROSS PROFITS FROM FUTURE SALES OF PRODUCT.  Full Article

Circassia Pharmaceuticals HY Pretax Loss From Cont Ops Of 14.3 Mln Stg
Thursday, 27 Sep 2018 02:01am EDT 

Sept 27 (Reuters) - Circassia Pharmaceuticals PLC ::HY UNDERLYING REVENUE FROM CONTINUING OPERATIONS £28.4M VERSUS £18.3M.HY UNDERLYING LOSS BEFORE TAX FROM CONTINUING OPERATIONS 14.3 MILLION STG VERSUS 19.2 MILLION STG.GROUP FACES A RANGE OF RISKS ASSOCIATED WITH BREXIT.  Full Article

Circassia Pharmaceuticals Says ‍Tudorza Meets Primary Endpoints In Ascent Study​
Monday, 4 Dec 2017 02:00am EST 

Dec 4 (Reuters) - CIRCASSIA PHARMACEUTICALS PLC ::TUDORZA® MEETS PRIMARY ENDPOINTS IN ASCENT STUDY​.TUDORZA® SUCCESSFULLY MET BOTH PRIMARY ENDPOINTS IN ASCENT PHASE IV STUDY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE​.  Full Article